
-
Pharming Group NasdaqGM:PHAR Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Location: Darwinweg 24, Leiden, 2333 CR, Netherlands | Website: https://www.pharming.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
6.242B
Cash
107.3M
Avg Qtr Burn
N/A
Short % of Float
-
Insider Ownership
0.00%
Institutional Own.
0.08%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Leniolisib Details Activated Phosphoniositide 3-kinase Delta Syndrome | Approved Quarterly sales | |
Leniolisib Details Activated Phosphoniositide 3-kinase Delta Syndrome | NDA Submission | |
KL1333 Details Mitochondrial disease, primary mitochondrial myopathies | Phase 3 Data readout | |
Leniolisib Details Immunodeficiency | Phase 2 Data readout | |
Leniolisib Details Immunodeficiency | Phase 2 Data readout |